<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00938405</url>
  </required_header>
  <id_info>
    <org_study_id>DSI-WCH-100</org_study_id>
    <nct_id>NCT00938405</nct_id>
  </id_info>
  <brief_title>Efficacy of Colesevelam in Subjects With Type 1 Diabetes Mellitus</brief_title>
  <official_title>Efficacy of Colesevelam in Subjects With Type 1 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado Denver School of Medicine Barbara Davis Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado Denver School of Medicine Barbara Davis Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized, double blind, parallel, placebo controlled clinical trial&#xD;
      evaluating the efficacy of colesevelam HCl in reducing LDL in subjects with type 1 diabetes&#xD;
      mellitus over a 12 week treatment period. The aim is to highlight the effect of colesevelam&#xD;
      on LDL cholesterol and glycemia in a type 1 diabetic population. The colesevelam group is&#xD;
      anticipated to demonstrate a mean reduction in LDL by 10% compared to the placebo group,&#xD;
      indicated by A1c and glycemic target range CGM readings.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized, double blind, parallel, placebo controlled clinical trial&#xD;
      evaluating the efficacy of colesevelam HCl in reducing LDL in subjects with type 1 diabetes&#xD;
      mellitus over a 12 week treatment period. Colesevelam is an orally administered bile acid&#xD;
      sequestrant approved as an adjunct for diet and exercise for lowering incidence of&#xD;
      hyperlipidemia, an important risk factor for long term cardiovascular health in the general&#xD;
      population and people living with diabetes. Use of colesevelam has been shown to concurrently&#xD;
      decrease low density lipoprotein cholesterol (LDL-C) and A1c in patients with type 2&#xD;
      diabetes. The exact mechanism is unknown. Our research aims to highlight the effect of&#xD;
      colesevelam on LDL and glycemia in a type 1 diabetic population.&#xD;
&#xD;
      This single-center study will enroll a maximum of 40 patients with LDL-C &gt; 100 and A1c values&#xD;
      between 6.5-9%, who will be randomized in a 1:1 fashion to either the study drug or placebo.&#xD;
      Visits will be conducted at screening, baseline, one month, two months, and three months. At&#xD;
      home, subjects will take 3.75 gms/day of colesevelam HCl or placebo throughout the study&#xD;
      duration. Laboratory analysis will be performed at various timepoints assessing A1c, fasting&#xD;
      lipid panel, c-peptide, glucagon-like-peptide-1 (GLP-1), and glucose-dependent insulinotropic&#xD;
      peptide (GIP). Continuous glucose monitoring (CGM) measurements will be obtained on all&#xD;
      patients for one week before each monthly visit to assess for above target range (ATR),&#xD;
      within target range (WTR), and below target range (BTR) glucose values and time spent in&#xD;
      hyperglycemic and hypoglycemic excursions.&#xD;
&#xD;
      The colesevelam group is anticipated to demonstrate a mean reduction in LDL by 10% compared&#xD;
      to the placebo group.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To demonstrate a 10% LDL reduction in type 1 diabetic subjects with initial LDL &gt; 100 after twelve weeks in the colesevelam group.</measure>
    <time_frame>12 weeks of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate colesevelam use for glucose control as measured by A1c using a 0.4% confidence interval at baseline and after one, two, and three months of therapy.</measure>
    <time_frame>12 weeks of treatment.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate colesevelam use for non-inferiority of percent of target range glucose values and time spent in hyper- and hypoglycemic ranges as determined by CGM readings at baseline and after one, two, and three months of therapy.</measure>
    <time_frame>12 weeks of treatment.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In addition change in insulin dose at one, two and three months from baseline will be evaluated.</measure>
    <time_frame>12 weeks of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <condition>Hyperlipidemias</condition>
  <arm_group>
    <arm_group_label>Colesevelam HCl</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Beginning at Visit 1, two weeks after screening, subjects in the active treatment group will take 3.75 gms/day of colesevelam HCl in the form of three 625 mg tablets with lunch and dinner or six 625mg tablets once daily with dinner.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparison group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Beginning at Visit 1, two weeks after screening, subjects in the comparison group will be administered placebo, taking 3.75 gms/day of colesevelam HCl in the form of three 625 mg tablets with lunch and dinner or six 625mg tablets once daily with dinner.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colesevelam HCl</intervention_name>
    <description>3.75 gms/day of colesevelam HCl in the form of three 625 mg tablets with lunch and dinner or six 625mg tablets once daily with dinner.</description>
    <arm_group_label>Colesevelam HCl</arm_group_label>
    <other_name>WELCHOL (colesevelam hydrochloride)</other_name>
    <other_name>Initial U.S. Approval: 2000</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo: 3.75 gms/day in the form of three 625 mg tablets with lunch and dinner or six 625mg tablets once daily with dinner.</description>
    <arm_group_label>Comparison group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All subjects will be on stable doses of insulin using MDI or CSII (Basal insulin-&#xD;
             Lantus or Levemir; Bolus- Humalog, Novolog, Apidra, Humulin Regular), for three months&#xD;
             prior to enrollment.&#xD;
&#xD;
          -  Type 1 diabetes duration &gt; 3 years.&#xD;
&#xD;
          -  6.5% ≤ A1c ≤ 9.0%.&#xD;
&#xD;
          -  Male or female ≥ 18 and ≤ 65 years of age.&#xD;
&#xD;
          -  Ability and willingness to adhere to the protocol including multiple daily oral doses&#xD;
             of study drug or placebo and week-long CGM wear.&#xD;
&#xD;
          -  LDL-C &gt; 100 mg/dl.&#xD;
&#xD;
          -  Willing to adhere to colesevelam dosage instructions, including administration of&#xD;
             drugs with a known interaction at least 4 hours prior to colesevelam. Females using&#xD;
             oral contraceptives containing ethinyl estradiol and norethindrone must be willing to&#xD;
             administer their doses at least four hours prior to using colesevelam.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Advanced retinopathy needing laser procedure or vitrectomy.&#xD;
&#xD;
          -  Unstable nephropathy (serum creatinine &gt; 2.0 mg/dl or macroproteinuria (albumin&#xD;
             excretion rate &gt; 200 ug/ min).&#xD;
&#xD;
          -  Any unexplained severe hypoglycemia within the last six months.&#xD;
&#xD;
          -  BMI &gt; 35.0.&#xD;
&#xD;
          -  Currently on a pre-existing bile acid sequestrant therapy, glyburide, levothyroxine,&#xD;
             phenytoin, or warfarin.&#xD;
&#xD;
          -  Pregnant, planning a pregnancy, or not using an adequate method of birth control.&#xD;
&#xD;
          -  Any other condition, as determined by the investigator, which could make the subject&#xD;
             unsuitable for the trial, impairs the subject's suitability for the trial, or impairs&#xD;
             the validity of the informed consent.&#xD;
&#xD;
          -  Use of any medication known to modify glucose values other than insulin (i.e.&#xD;
             corticosteroids or oral antidiabetics).&#xD;
&#xD;
          -  A history of bowel obstruction.&#xD;
&#xD;
          -  Serum triglyceride (TG) concentrations &gt;500 mg/dL.&#xD;
&#xD;
          -  A history of hypertriglyceridemia induced pancreatitis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Satish K Garg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado Denver/ Barbara Davis Center for Diabetes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barbara Davis Center for Diabetes</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Bays HE, Goldberg RB, Truitt KE, Jones MR. Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects. Arch Intern Med. 2008 Oct 13;168(18):1975-83. doi: 10.1001/archinte.168.18.1975.</citation>
    <PMID>18852398</PMID>
  </reference>
  <reference>
    <citation>Goldberg RB, Fonseca VA, Truitt KE, Jones MR. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Arch Intern Med. 2008 Jul 28;168(14):1531-40. doi: 10.1001/archinte.168.14.1531.</citation>
    <PMID>18663165</PMID>
  </reference>
  <reference>
    <citation>Fonseca VA, Rosenstock J, Wang AC, Truitt KE, Jones MR. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care. 2008 Aug;31(8):1479-84. doi: 10.2337/dc08-0283. Epub 2008 May 5.</citation>
    <PMID>18458145</PMID>
  </reference>
  <reference>
    <citation>Goldfine AB, Fonseca VA. The use of colesevelam HCl in patients with type 2 diabetes mellitus: combining glucose- and lipid-lowering effects. Postgrad Med. 2009 May;121(3 Suppl 1):13-8. doi: 10.3810/pgm.2009.05.suppl53.288. Review.</citation>
    <PMID>19494473</PMID>
  </reference>
  <reference>
    <citation>Staels B. A review of bile acid sequestrants: potential mechanism(s) for glucose-lowering effects in type 2 diabetes mellitus. Postgrad Med. 2009 May;121(3 Suppl 1):25-30. doi: 10.3810/pgm.2009.05.suppl53.290. Review.</citation>
    <PMID>19494475</PMID>
  </reference>
  <reference>
    <citation>Garg SK, Kelly WC, Voelmle MK, Ritchie PJ, Gottlieb PA, McFann KK, Ellis SL. Continuous home monitoring of glucose: improved glycemic control with real-life use of continuous glucose sensors in adult subjects with type 1 diabetes. Diabetes Care. 2007 Dec;30(12):3023-5. Epub 2007 Sep 11.</citation>
    <PMID>17848608</PMID>
  </reference>
  <verification_date>May 2014</verification_date>
  <study_first_submitted>July 10, 2009</study_first_submitted>
  <study_first_submitted_qc>July 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2009</study_first_posted>
  <last_update_submitted>May 19, 2014</last_update_submitted>
  <last_update_submitted_qc>May 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Colorado Denver School of Medicine Barbara Davis Center</investigator_affiliation>
    <investigator_full_name>Satish K. Garg</investigator_full_name>
    <investigator_title>Professor of Medicine &amp; Pediatrics</investigator_title>
  </responsible_party>
  <keyword>type 1 diabetes mellitus</keyword>
  <keyword>colesevelam</keyword>
  <keyword>LDL</keyword>
  <keyword>cholesterol</keyword>
  <keyword>A1c</keyword>
  <keyword>target range glucose values</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colesevelam Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

